Evidence map›Paper›PMID 41734361›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon, Toby Talbot and 10 more

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Arnaud ScherpereelUniversity of Lille, CHU Lille, INSERM U1189 OncoThAI, ONCOLille, Lille, France.ORCID 0000-0002-7607-1863
Paul BaasThe Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, the Netherlands.ORCID 0000-0001-7018-9556
Anna K NowakUniversity of Western Australia, Perth, WA, Australia.ORCID 0000-0002-9317-9526
Anne S TsaoUniversity of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-0505-6639
Nobukazu FujimotoOkayama Rosai Hospital, Okayama, Japan.
Solange PetersLausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0002-0412-7143
Aaron S MansfieldMayo Clinic, Rochester, MN.ORCID 0000-0002-9483-6903
Sanjay PopatThe Royal Marsden Hospital, London, United Kingdom.ORCID 0000-0003-2087-4963
Yolanda Bautista AragonCentro Médico Nacional Siglo XXI, Mexico City, Mexico.
Toby TalbotThe Sunrise Centre, Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom.
Francesco GrossiMedical Oncology Division, IRCCS Policlinico San Martino, Genova, Italy.ORCID 0000-0001-8412-3136
Dariusz KowalskiMaria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID 0000-0002-9452-3229
Muhammet A KaplanDicle University, Diyarbakir, Turkey.
Andrés Felipe CardonaLuis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.ORCID 0000-0003-3525-4126
Raheela SoomroBristol Myers Squibb, Princeton, NJ.
Nan HuBristol Myers Squibb, Princeton, NJ.
Adam LeeBristol Myers Squibb, Uxbridge, United Kingdom.ORCID 0000-0001-8834-1296
Virginia IpBristol Myers Squibb, Princeton, NJ.
Yu-Han HungBristol Myers Squibb, Princeton, NJ.ORCID 0000-0002-3278-3201
Gérard ZalcmanUniversité Paris Cité, Bichat-Claude Bernard Hospital, Thoracic Oncology Department, AP-HP. Nord Cancer Institute, Paris, France.ORCID 0000-0002-0343-9575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14%

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsIpilimumabMesotheliomaNivolumabPleural NeoplasmsAgedFemaleHumansMaleMesothelioma, MalignantMiddle AgedTreatment OutcomeIpilimumabNivolumab

Identifiers

PMID41734361
PMCPMC13001902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.